# Moximed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/moximed

- Industry: Medical Devices & Equipment
- Headquarters: Fremont, US
- Website: www.moximed.com/
- Total disclosed funding: $250M
- Latest round: Series D (Aug 13, 2024)
- Investors on record: 12

## About

Based in California, US, and founded in 2006 by co-founders Anton Clifford, Ph.D., and Joshua Makower, MD, Moximed, Inc., formerly known as ExploraMed NC, operates as a provider of implantable shock absorbers for knee osteoarthritis to patients looking for non-surgical relief from joint pain and dysfunction. In August 2024, Moximed, Inc. raised USD 91 million in Series D funding led by Patient Square Capital, LP, with participation from New Enterprise Associates, Future Fund, Advent Life Sciences, Gilde Healthcare Partners, Vertex Ventures HC, GBS Venture Partners, Morgenthaler Ventures, Cormorant Asset Management, and Warren Point Capital. As of 2024, the company is led by its CEO, Christopher Gleason.

The company provides a wide range of medical device products, such as the MISHA Knee System, which includes an implantable shock absorber intended to reduce knee pain and improve function. Additionally, the firm also provides services such as clinical research and patient support for the MISHA Knee System.

## Funding rounds

- Series D, Aug 13, 2024, $91M — Morgenthaler Ventures, New Enterprise Associates, GBS Venture Partners, Gilde Healthcare, Future Fund, Cormorant Asset Management, Vertex Ventures HC, Advent Life Sciences, Patient Square Capital, Warren Point Capital
- Series C, Aug 16, 2022 — Morgenthaler Ventures, New Enterprise Associates, GBS Venture Partners, Gilde Healthcare, Future Fund, Vertex Ventures HC, Advent Life Sciences
- Series C, Mar 15, 2017, $50M — Morgenthaler Ventures, New Enterprise Associates, GBS Venture Partners, Gilde Healthcare, Future Fund, Vertex Ventures HC, Advent Life Sciences
- Series B, Jan 27, 2016, $13M — New Enterprise Associates, GBS Venture Partners, Gilde Healthcare, Vertex Holdings
- Series B, Apr 23, 2015, $20M — Morgenthaler Ventures, New Enterprise Associates, GBS Venture Partners, Gilde Healthcare, Vertex Ventures HC
- Series A, Dec 5, 2011, $2.6M — Frazier Healthcare Partners, Morgenthaler Ventures, New Enterprise Associates, Gilde Healthcare
- Series A, May 26, 2011, $43M — Frazier Healthcare Partners, Morgenthaler Ventures, New Enterprise Associates, GBS Venture Partners, Gilde Healthcare
- Series A, Aug 5, 2009, $10M — Morgenthaler Ventures, New Enterprise Associates
- Series A, Jun 9, 2008, $21M — Morgenthaler Ventures, New Enterprise Associates

## Investors

- Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series A, Series B, Series C, Series D
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B, Series C, Series D
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A
- GBS Venture Partners (https://capitalatlas.ai/funds/gbs-venture-partners) — Series A, Series B, Series C, Series D
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A, Series B, Series C, Series D
- Vertex Ventures HC (https://capitalatlas.ai/funds/vertex-ventures-hc) — Series B, Series C, Series D
- Vertex Holdings (https://capitalatlas.ai/funds/vertex-holdings) — Series B
- Future Fund — Series C, Series D
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series C, Series D
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series D
- Patient Square Capital (https://capitalatlas.ai/funds/patient-square-capital) — Series D
- Warren Point Capital (https://capitalatlas.ai/funds/warren-point-capital) — Series D